ViiV Healthcare presents positive interim data showing Vocabria (cabotegravir) and Rekambys (rilpivirine), the first long-acting HIV-treatment regimen, can be implemented successfully in a variety of European healthcare settings
The CARISEL study showed most people living with HIV who started treatment felt positive about the long-acting regimen, a sentiment shared by healthcare teams For media and investors only ViiV
Source: finanznachrichten.de